Last reviewed · How we verify
Recombinant human C1 esterase inhibitor
At a glance
| Generic name | Recombinant human C1 esterase inhibitor |
|---|---|
| Also known as | SHP623 |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection (PHASE2)
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation (PHASE2)
- Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) (PHASE4)
- Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema (PHASE3)
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) (PHASE2)
- Patient Registry to Evaluate the Real-world Safety of Ruconest®
- Prevention of Acute Kidney Injury in Patients With NSTEMI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant human C1 esterase inhibitor CI brief — competitive landscape report
- Recombinant human C1 esterase inhibitor updates RSS · CI watch RSS
- Shire portfolio CI